Because direct compression of norfloxacin base at 400 mg per tablet is typically rejected during compaction trials due to poor flow, elastic recovery, and capping tendency, aqueous high-shear wet granulation remains the default manufacturing route for uncoated immediate-release tablets. The formulation addition ratio is calculated on dry granulate mass: norfloxacin base 400 mg per unit, microcrystalline cellulose 20–40% w/w, lactose monohydrate 20–40% w/w, crospovidone or sodium starch glycolate 2–5% w/w, povidone K30 dissolved in purified water as 3–5% w/w of dry granulate, and magnesium stearate 0.5–1.0% w/w added after dry milling. The downstream production process is executed in a jacketed high-shear granulator with impeller speed 200–300 rpm and chopper speed 1,500–3,000 rpm; wet massing time is held between 90 s and 180 s, and endpoint is controlled by impeller torque and visual consistency rather than by timer alone. The wet mass is discharged through a 4.0 mm screen into a fluid bed dryer, where inlet air at 60–70°C maintains product temperature at 30–40°C until loss on drying reaches 1.5–2.5%; over-drying below 1.0% increases brittle fracture and capping on compression, while residual moisture above 2.5% promotes picking and sticking on punch faces. Dried granules are milled through a 1.0 mm screen and lubricated in a bin blender for 3–5 min after 15 min of prior blending; prolonged lubrication beyond 5 min can reduce tensile strength through shear-induced magnesium stearate delamination on granule surfaces. Compression is performed on a rotary tablet press to hardness 8–14 kP, thickness 5.0–6.0 mm, and weight variation within ±5%; in-process limits follow 21 CFR 211.110, and finished tablets must comply with the current USP–NF Norfloxacin Tablets monograph, USP ‹711› dissolution, USP ‹905› uniformity of dosage units, and ICH Q3D elemental impurities. The terminal product type is an uncoated 400 mg oral tablet intended for urinary tract infections, normally packaged in opaque PVC/PVDC/aluminium blister to limit photodegradation. The operational boundary is explicit: granulation water amount must be revalidated for different norfloxacin base particle size distributions, and the solid oral formulation is not designed to contain polyvalent cation-containing excipients that would otherwise form poorly absorbable chelates in the gastrointestinal environment.

In coating suites processing norfloxacin tablet cores under ICH Q1B light exposure, a photoprotective film is a stability-critical operation rather than a cosmetic step. The addition ratio is expressed as dry polymer weight gain: an HPMC-based or PVA-based ready-mix coating dispersion at 12–15% solids is applied to achieve 3.0–4.0% w/w tablet weight gain; the dry film contains titanium dioxide at 20–30% w/w and a plasticizer such as triacetin at 8–10% of polymer solids. The downstream production process uses a perforated pan coater with pan speed 6–10 rpm, atomizing air pressure 1.5–2.5 bar, spray rate 80–120 g/min per gun, inlet air temperature 55–65°C, and bed temperature 38–42°C; exhaust humidity is monitored to avoid overwetting, which produces orange-peel roughness and logo bridging on the crown. Cores are preheated until bed temperature reaches 38°C before spraying begins, and coating is continued without interruption because start-stop cycles create inhomogeneous film thickness around the tablet band. End-product types are film-coated 400 mg norfloxacin tablets with reduced surface photodegradation, improved swallowability, and lower dusting in high-speed packaging; the film does not eliminate the need for opaque primary packaging because norfloxacin base can undergo yellowing even beneath translucent films. Compliance for the coating operation falls under 21 CFR 211.65 equipment construction and 21 CFR 211.110 in-process control, while the finished product must still meet USP ‹711› and USP ‹905›. Operational limitations include the need to re-qualify spray nozzle overlap after any change in pan loading and the incompatibility of certain iron oxide pigments with norfloxacin in acidic microenvironments if the film is cracked or compromised during long-term storage.

What Limits Capsule Fill Weight Variance When Norfloxacin Base Is Blended with Lactose Monohydrate?

The limiting variable is not API assay but powder flow and electrostatic charge retention after low-shear blending. Norfloxacin base is a hydrophobic, light-sensitive powder with poor aqueous solubility at neutral pH; when filled into hard gelatin or HPMC capsules, the formulation addition ratio often places norfloxacin base at 400 mg per capsule, with lactose monohydrate or mannitol at 20–30% w/w, microcrystalline cellulose at 20–30% w/w, croscarmellose sodium at 2–4% w/w, and magnesium stearate at 0.5–1.0% w/w, yielding a fill weight of 600–700 mg for a size 0 or 00 capsule. The mix is blended in a bin blender at 12 rpm for 15 min before lubricant addition and then for 3–5 min after lubricant; excessive mixing above 5 min after magnesium stearate addition is avoided because it can retard dissolution. An automatic capsule filler with dosator or tamping-pin configuration is operated at 60,000–80,000 capsules/h under 45–55% relative humidity to control static; hard gelatin capsules require 13–16% shell moisture to prevent brittleness, while HPMC capsules tolerate lower humidity but may show slower dissolution in acid media. In-process weight variation must comply with 21 CFR 211.110, and finished capsules must satisfy USP ‹905› uniformity of dosage units and USP ‹711› dissolution; dissolution testing for norfloxacin capsules is typically performed in 900 mL of 0.1 N hydrochloric acid at 37°C with USP apparatus 2 at 50 rpm, with an acceptance criterion of not less than 80% dissolved in 30 min unless the current monograph specifies otherwise. Terminal product types are hard gelatin and HPMC oral capsules for adult patients who require a swallowed solid dose with faster disintegration than a film-coated tablet. Operational boundaries include the incompatibility of norfloxacin base with polyvalent cations in co-formulated excipients, and pre-drying may be required if blend moisture exceeds 2.0% before encapsulation.

Once an aqueous binder solution is sprayed onto a norfloxacin–sucrose granulation in a top-spray fluid bed, endpoint moisture governs whether the sachet product will pour cleanly or clump under tropical storage. Granules for oral suspension are formulated with norfloxacin base at 400 mg per single-dose sachet, sucrose or sorbitol at 30–50% w/w, xanthan gum at 0.2–0.5% w/w as suspending agent, sodium citrate at 0.5–1.5% w/w for pH buffering, colloidal silicon dioxide at 0.5–1.0% w/w as flow aid, and a non-reducing flavour at 0.5–1.0% w/w. The binder solution is povidone K30 at 5% w/v in purified water, sprayed from a top-spray fluid bed at 150–250 g/min with inlet air 60–75°C and product temperature held at 30–35°C; drying continues until residual moisture is ≤2.0% and the particle size distribution shows 80% of mass between 180 µm and 850 µm. The dried granules are filled into sachets on form-fill-seal lines with nitrogen-flushed aluminium laminate to limit photodegradation and moisture ingress. Compliance for granules requires USP ‹711› dissolution, USP ‹905› uniformity of dosage units where single-dose presentation is used, ICH Q6A dose delivery, and 21 CFR 211.110 in-process sampling; the oral suspension after reconstitution must meet the same pharmacopoeial standard for dose content and stability as the dry granule. End-product types are single-dose granules for oral suspension or multi-dose granules for reconstitution into fixed-volume bottles, intended for patients with dysphagia or pediatric dose adjustment where a scored tablet is unsuitable. Operational boundaries include avoiding reducing-sugar excipients that can undergo Maillard browning with the secondary amine of norfloxacin under heat, and the reconstituted suspension must be protected from direct sunlight because norfloxacin base is photolabile in aqueous media.

Terminal Sterilization of Norfloxacin Infusion Concentrate at 121°C Without Chelation-Induced Instability

Norfloxacin base has pH-dependent solubility: aqueous solubility below 0.3 mg/mL near pH 7 necessitates acidification to form a water-soluble salt in situ, typically targeting a final pH of 3.5–4.5 and a norfloxacin base concentration of 2 mg/mL in a 100 mL infusion container. The formulation addition ratio includes norfloxacin base 2 mg/mL, a compendial acidifying agent sufficient to achieve pH 3.5–4.5, sodium chloride or dextrose to isotonicity of 280–310 mOsm/kg, disodium edetate at 0.01% w/v as a chelator to suppress metal-catalysed oxidation, and water for injection. The downstream production process is performed under nitrogen overlay in a closed mixing vessel; the API is added slowly to the acidified aqueous phase at 20–25°C to avoid local supersaturation and precipitation on vessel walls. The bulk solution is filtered through a 0.45 µm prefilter and then a 0.22 µm sterilising-grade PVDF filter before filling into amber Type I glass vials or non-PVC infusion bags. Terminal sterilization is conducted at 121°C for 15 min with an F₀ of ≥8 min, but only after thermal challenge studies demonstrate that related substance levels remain within the current monograph limits; published data for this exact norfloxacin base formulation are limited, so production lines must generate spore challenge and container mapping data before parametric release is considered. Compliance for the injectable dosage form includes USP ‹1›, USP ‹71›, USP ‹85›, USP ‹788›, USP ‹790›, ISO 13408-1:2022, and 21 CFR 210.1/211.113. End-product types are sterile ready-to-use infusion solutions in 100 mL containers or pharmacy admixture concentrates for dilution; neither formulation may be stored in direct light, and contact with iron, copper, or aluminium equipment surfaces must be controlled because fluoroquinolone-metal complexes can precipitate and reduce potency.